Our research program is centered on the role of non-coding RNAs (in particular microRNAs) in genetic, microbial, dietary, and environmental control of health and disease. The primary disease areas of focus are diabetes, dyslipidemia, gastrointestinal (GI) disorders including Crohn's disease, and most recently, liver/GI cancers. Our laboratory paradigm is highly interdisciplinary, at the interface of genomics, physiology, bioinformatics, and molecular biology.
Active research areas in the lab include:
- Role of microRNAs and lncRNAs in the regulation of processes relevant to metabolic disease and cancer
- Contribution of microRNAs and lncRNAs to GI stem cell function and intestinal epithelial homeostasis
- Utility of non-coding RNAs as candidate molecular stratifiers and prognostic determinants of GI diseases such as Crohn's
- The role of microRNAs in conferring regulatory stability in the liver, intestine, and pancreatic islet in the face of environmental perturbations (diet, microbes, toxicants)
- Novel forms of intercellular communication in health and disease via regulated transfer of small RNAs
B.E Peck, A.T. Mah, W.A. Pitman, S. Ding, P.K. Lund and P. Sethupathy (2017). Functional transcriptomics in diverse intestinal epithelial cell types reveals robust microRNA sensitivity in intestinal stem cells to microbial status. Journal of Biological Chemistry, 292:2586-2600.
A.R. Coffey, T.L. Smallwood, J. Albright, K. Hua, M. Kanke, D. Pomp, B.J. Bennett* and P. Sethupathy* (2017). Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDL cholesterol in murine diet-induced dyslipidemia. Physiological Genomics, doi:10.1152/physiolgenomics.00050.2017.
B.C. Peck, M.T. Shanahan, A.P. Singh and P. Sethupathy (2017). Gut microbial influences on the mammalian intestinal stem cell niche. Stem Cells International, doi:10.1155/2017/5604727.
J. Baran-Gale, J. E. Purvis and P. Sethupathy (2016). An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells. RNA, 22:1592-1603.
P. Sethupathy (2016). The promise and challenge of therapeutic microRNA silencing in diabetes. Current Diabetes Reports, 16:52.
T. Oikawa, E. Wauthier, T.A. Dinh, S. R. Selitsky, A. Reyna-Neyra, G. Carpino, R. Levine, V. Cardinale, E. Gaudio, D. Alvaro, D. Klimstra, N. Carrasco, P. Sethupathy* and L.M. Reid* (2015). Model of fibrolamellar hepatocellular carcinoma reveals striking enrichment in cancer stem cells. Nature Communications, 6:8070.
C.L. Kurtz*, B.C. Peck*, E.E. Fannin, C. Beysen, S.R. Landstreet, S. Ding, V. Turaga, P.K. Lund, S. Turner, S. B. Biddinger, K.C. Vickers, and P. Sethupathy (2014). microRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes, 63:3141-8.
T.S. Furey and P. Sethupathy (2013). Genetics driving epigenetics. Science, 342:705-706.
[Complete list of publications]